Q1 2025 EPS Estimates for Intellia Therapeutics, Inc. (NASDAQ:NTLA) Boosted by Zacks Research

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Equities research analysts at Zacks Research upped their Q1 2025 earnings per share (EPS) estimates for shares of Intellia Therapeutics in a report issued on Wednesday, July 17th. Zacks Research analyst R. Department now forecasts that the company will earn ($1.43) per share for the quarter, up from their prior forecast of ($1.52). The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($4.98) per share. Zacks Research also issued estimates for Intellia Therapeutics’ Q2 2025 earnings at ($1.50) EPS, Q3 2025 earnings at ($1.55) EPS, Q4 2025 earnings at ($1.55) EPS, FY2025 earnings at ($6.03) EPS, Q1 2026 earnings at ($2.12) EPS, Q2 2026 earnings at ($1.69) EPS and FY2026 earnings at ($7.05) EPS.

Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Thursday, May 9th. The company reported ($1.06) earnings per share for the quarter, beating the consensus estimate of ($1.35) by $0.29. The firm had revenue of $28.94 million during the quarter, compared to analysts’ expectations of $15.60 million.

NTLA has been the topic of several other research reports. Citigroup cut their price target on Intellia Therapeutics from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Friday, May 10th. Wedbush reiterated a “neutral” rating and set a $29.00 target price on shares of Intellia Therapeutics in a research note on Tuesday, April 23rd. Canaccord Genuity Group restated a “buy” rating and issued a $73.00 price target on shares of Intellia Therapeutics in a research note on Thursday, June 27th. StockNews.com raised shares of Intellia Therapeutics to a “sell” rating in a report on Thursday, June 27th. Finally, BMO Capital Markets raised their price objective on shares of Intellia Therapeutics from $62.00 to $70.00 and gave the stock an “outperform” rating in a report on Friday, May 10th. One analyst has rated the stock with a sell rating, four have given a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat, Intellia Therapeutics has an average rating of “Moderate Buy” and an average price target of $69.00.

Intellia Therapeutics Price Performance

Intellia Therapeutics stock opened at $26.46 on Monday. The firm’s fifty day moving average price is $24.29 and its 200 day moving average price is $25.52. The company has a market capitalization of $2.55 billion, a price-to-earnings ratio of -4.94 and a beta of 1.82. Intellia Therapeutics has a 12-month low of $19.37 and a 12-month high of $43.56.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Avidity Partners Management LP grew its position in shares of Intellia Therapeutics by 18.0% during the 4th quarter. Avidity Partners Management LP now owns 447,434 shares of the company’s stock valued at $13,642,000 after buying an additional 68,334 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in Intellia Therapeutics by 2.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 700,228 shares of the company’s stock valued at $21,350,000 after purchasing an additional 18,987 shares during the period. ARK Investment Management LLC grew its stake in Intellia Therapeutics by 14.7% during the 4th quarter. ARK Investment Management LLC now owns 11,412,449 shares of the company’s stock worth $347,966,000 after buying an additional 1,463,820 shares during the last quarter. American Century Companies Inc. grew its stake in Intellia Therapeutics by 5.9% during the 3rd quarter. American Century Companies Inc. now owns 267,213 shares of the company’s stock worth $8,449,000 after buying an additional 14,863 shares during the last quarter. Finally, Raymond James Financial Services Advisors Inc. increased its position in Intellia Therapeutics by 13.3% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 36,225 shares of the company’s stock worth $1,104,000 after buying an additional 4,255 shares during the period. 88.77% of the stock is currently owned by institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.